China Biosimilars Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

The China Biosimilars Market was valued at USD 4.6 billion in 2025 and is estimated to grow at a CAGR of 17.5% to reach USD 23.6 billion by 2035.

The market is experiencing rapid development as healthcare providers, patients, and policymakers increasingly focus on improving access to affordable biologic therapies. The growing incidence of chronic and complex health conditions across China is creating a stronger need for cost-efficient treatment options that can deliver comparable therapeutic benefits to established biologic medicines. A combination of a large patient population, expanding healthcare infrastructure, urban development, and increasing demand for long-term disease management solutions is supporting biosimilar adoption across the country. Government initiatives focused on healthcare affordability, broader reimbursement coverage, and ongoing medical system improvements are further strengthening market penetration. Biosimilars are becoming an important part of China’s pharmaceutical landscape by helping reduce treatment expenses while expanding access to advanced biologic therapies. Their increasing acceptance among healthcare professionals, hospitals, specialty treatment centers, and outpatient facilities is creating a favorable environment for continued market expansion.

Biosimilars are biologic medicines designed to closely match already approved reference products while maintaining comparable standards for safety, effectiveness, and quality. In China, these alternatives are improving availability of advanced biologic treatments by offering more affordable options compared with original biologic therapies, supporting wider patient access.

The recombinant glycosylated proteins segment held a 65.3% share in 2025. The strong performance of this segment is supported by increasing utilization of glycosylated biologic therapies across major treatment areas. Recombinant glycosylated proteins, including therapies based on monoclonal antibodies and erythropoietin, continue to experience strong demand due to their importance in managing serious and long-term medical conditions. Their established clinical value and growing use within hospitals and specialized healthcare facilities have contributed significantly to segment growth. The increasing requirement for effective treatments in areas such as oncology, anemia management, and immune-related disorders continues to support the adoption of these biosimilar products throughout China’s healthcare system.

The in-house manufacturing segment reached USD 2.8 billion in 2025. The segment’s strong position is linked to the growing number of vertically integrated biopharmaceutical companies that prefer maintaining internal manufacturing capabilities to improve quality management, regulatory alignment, and production control. Expanding investments in domestic production facilities, advanced bioprocessing technologies, and manufacturing infrastructure are helping companies enhance operational efficiency, reduce production costs, shorten development timelines, and strengthen supply chain stability. These advantages continue to encourage greater reliance on internal manufacturing models across China’s biosimilars sector.

Major players operating in the China biosimilars industry include Shanghai Henlius Biotech, BeiGene, Qilu Pharmaceutical, Innovent Biologics, Tonghua Dongbao Pharmaceutical, Akeso, Mabwell Bioscience, Hengrui Medicine, Bio-Thera Solutions, Junshi Biosciences, 3SBio, RemeGen, Hisun Pharmaceutical, and Gan & Lee Pharmaceuticals. Companies operating in the China biosimilars market are focusing on expanding production capacity, strengthening research and development capabilities, and improving manufacturing efficiency to secure a stronger market position. Leading organizations are investing in advanced biotechnology platforms, regulatory expertise, and quality control systems to accelerate product approvals and commercialization. Strategic collaborations, licensing agreements, and partnerships are also being used to expand product portfolios and access new therapeutic areas. Companies are increasingly prioritizing domestic manufacturing expansion to improve supply reliability and cost competitiveness.

Comprehensive Market Analysis and Forecast

• Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
• Competitive landscape with Porter’s Five Forces and PESTEL analysis
• Market size, segmentation, and regional forecasts
• In-depth company profiles, business strategies, financial insights, and SWOT analysis

This product will be delivered within 2-4 business days.